Alina Ecaterina Jucan | Molecular Biology | Research Excellence Award

Published on by Medical Lab Scientist

Dr. Alina Ecaterina Jucan | Molecular Biology | Research Excellence Award

Doctor | University of Medicine and Pharmacy | Romania

Dr. Alina Ecaterina Jucan is a research-oriented scholar whose work contributes to the advancement of her field through focused investigation and peer-reviewed dissemination. Her academic output comprises 7 published documents, reflecting consistent engagement with scholarly research and evidence-based inquiry. These publications have collectively received 51 citations, indicating growing recognition and uptake of her findings within the research community. With an h-index of 4, her work demonstrates both productivity and measurable impact, highlighting publications that have achieved sustained citation performance. Her research emphasizes methodological rigor, analytical clarity, and relevance to current scientific and clinical questions, contributing to the broader body of knowledge and supporting translational relevance where applicable. Through her publications, she has addressed emerging challenges, refined existing concepts, and added incremental value to ongoing academic discourse. Her citation metrics underscore the visibility and influence of her research outputs, positioning her as an active contributor to her domain with a developing and credible scholarly profile grounded in peer-reviewed research excellence.

Citation Metrics (Scopus)

60

45

30

15

0

 

51
Citations

7
Documents

4
h-index

Citations

Documents

h-index

Featured Publications

Heming Li | Molecular Biology | Research Excellence Award

Published on by Medical Lab Scientist

Dr. Heming Li | Molecular Biology | Research Excellence Award

Doctor | The first hospital of China Medical University | China

Dr. Heming Li is an oncology clinician-scientist whose research has generated 1,045 citations across 37 scientific documents with an h-index of 17, reflecting a sustained impact on translational cancer science. His work centers on liquid biopsy innovations, particularly circulating tumor cells (CTCs), tumor invasion and metastasis, and immunotherapy biomarkers in lung, gastric, and hepatobiliary cancers. Dr. Li is recognized for pioneering one of China’s earliest and most sensitive cell-surface vimentin (CSV)–based CTC detection platforms, integrating negative and positive enrichment to enhance diagnostic accuracy, reduce costs, and enable real-time monitoring of tumor evolution. His research spans EMT regulation, immune escape, metabolic reprogramming, and multi-omics characterization of metastatic pathways, leading to first-author and corresponding-author publications in high-impact journals such as The Lancet, Journal of Hematology & Oncology, Journal of Experimental & Clinical Cancer Research, Molecular Cancer, Cancer Letters, and Cell Death & Disease. He has elucidated mechanisms including IGF-IR signaling, KDM4A/STAT3-driven tumor progression, ICAM-1-mediated microenvironmental adaptation, and PD-L1 expression on CSV⁺ CTCs as a prognostic marker in gastric cancer. His recent studies have also advanced understanding of FGL1 as an immune checkpoint target and the biological significance of TROP2 in cancer therapeutics. As principal investigator, he has secured major national and provincial funding, including NSFC General and Young Programs, to study CTC-based biomarkers, immunotherapy prediction models, and metastasis-driving pathways. Through sustained contributions across liquid biopsy technology, molecular oncology, and clinically actionable biomarker development, Dr. Li has established a leading research profile shaping the future of precision cancer care.

Profile: Scopus  

Featured Publications